U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
The FDA approved Gilead's Trodelvy for first-line treatment of metastatic triple-negative breast cancer, expanding its use from later lines of therapy to the initial treatment setting. Approval was supported by Phase 3 data showing a 38% reduction in risk of disease progression or death as monotherapy and a 35% reduction when combined with Keytruda.
Key figures
- Drug Name
- Trodelvy (sacituzumab govitecan-hziy)
- Phase Of Trial
- Phase 3
- Patients treated globally
- 75000
- Pfs risk reduction ascent 03
- 38%
- Pfs risk reduction ascent 04
- 35%
- Duration of response ascent 03
- 12.2 months
- Duration of response ascent 04
- 16.5 months
- Trop2 expression in breast lung
- >90%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.